Barely Significant
← all excerpts

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.

ACR Open Rheumatol · 2022 · PMC9190216 · PMID 35157371

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)
There was a trend toward a lower annualized flare rate in the placebo group (0.64 vs 0.43); however, this did not reach statistical significance ( P = 0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.